Camurus investor relations material
Listen to the latest call from Camurus
Camurus AB is a pharmaceutical company developing and commercializing medicines for severe and chronic conditions. Camurus AB's product portfolio includes PRADAXA, which is indicated for the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; TYSABRI for multiple sclerosis (MS) and psoriatic arthritis; DIFICID for antibiotic-associated diarrhea (AAD); EURAX for ulcerative colitis; and ORAPAVAN for nephrotic syndrome. Camurus AB is based in Lund, Sweden.
Ticker
CAMXCountry
SE